News and events

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, and Mithra Pharmaceuticals (Euronext Brussels: MITRA) announce a new collaboration to ...

July 15, 2021

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has generated data on its COVID-19 antibody ...

July 13, 2021

ExeVir Announces Close of $50 million/ EUR42 million Series A Financing

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising ...

March 16, 2021

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection against SARS-COV-2 and related coronaviruses

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, announces publication in BioRxiv of a paper by VIB scientists showing, ...

March 9, 2021

ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors

ExeVir, which is developing nanobody therapies providing broad protection against viral infections, including a lead candidate for coronaviruses, today announced that Michel Kazatchkine and Stef ...

November 3, 2020